Hymovis®, which was recently approved by the FDA in the U.S., is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties

PARSIPPANY, N.J., Nov. 2, 2015 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will present Hymovis® (high molecular weight viscoelastic hyaluronan) at the American…

Fidia Farmaceutici’s Italian excellence grows in the US market with its latest generation hyaluronic acid

The FDA’s Center for Devices and Radiological Health (CDRH) has approved the PMA (Pre Market Approval) application for Hymovis from Fidia Farmaceutici, indicated for the intra-articular therapy of osteoarthritis based on hyaluronic acid, designed to remain longer in the joint. This information comes…
Fidia Pharma USA, Inc. will be exhibiting at the Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in New Orleans, LA, March 11-15, 2014. Please come and see us at booth 973.We will be exhibiting our flagship product HYALGAN® (sodium hyaluronate, intra-articular injections for…

New addition in the company's dermatological portfolio

Abano Terme (Italy) and Milan (Italy) April 3, 2013 - Fidia Farmaceutici S.p.A. (Abano Terme, Italy) and BMG Pharma S.r.l. (Milan, Italy) are pleased to announce that they have signed an exclusive distribution agreement granting Fidia the rights to promote, market and sell BMG Pharma's topical gel…

Fidia Pharma USA Inc, to distribute the product online

Hyalo GYN® supplements the body's natural hydrating function, and is intended for use as a hydrating /lubricating agent in patients suffering from vaginal dryness of various origins, and micro-lesions of the epithelium that can result from a poorly lubricated environment. It was developed especially…

Organizzato da Fidia con il patrocinio dell'Università degli Studi di Padova

Patrocinato dall'Universita' di Padova e promosso da Fidia farmaceutici, il convegno trattera' dell'osteoartrosi, la piu' comune forma di artrite che si caratterizza per la degenerazione della cartilagine, tessuto che garantisce elasticita' alle parti dello scheletro sottoposte quotidianamente a…

Commercial rights to Hyalgan transitioned from Sanofi back to Fidia, the brand's owner and manufacturer

Wholly-owned subsidiary, Fidia Pharma USA Inc, engages Interpace BioPharma, LLC. to handle distribution and promotional support

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. ("Fidia") announced today that it has assumed responsibility for distributing and promoting the osteoarthritis (OA) treatment, Hyalgan (sodium hyaluronate), in the United States through its wholly-owned subsidiary, Fidia…

Genzyme's EP patent has been finally revoked in its entirety by the EPO Board of Appeal

Fidia Farmaceutici S.p.A. (Abano Terme, Italy) announces that the opposition they filed against European Patent EP 0466300 B1 to Genzyme Corporation (Cambridge, MA, USA) has been entirely successful. Indeed, Genzyme's EP patent has been finally revoked in its entirety by the EPO Board of Appeal…

The U.S. FDA has accepted the IND application for the development of a 140mg Diclofenac Sodium Matrix Patch for the topical treatment of acute pain

Applied Pharma Research sa (APR), and Fidia Farmaceutici SpA (Fidia) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for the development of a 140mg Diclofenac Sodium Matrix Patch for the topical treatment of acute pain due…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics